Targeting CB2 and TRPV1: Computational Approaches for the Identification of Dual Modulators

Both metabotropic (CBRs) and ionotropic cannabinoid receptors (ICRs) have implications in a range of neurological disorders. The metabotropic canonical CBRs CB1 and CB2 are highly implicated in these pathological events. However, selective targeting at CB2 versus CB1 offers optimized pharmacology due to the absence of psychoactive outcomes. The ICR transient receptor potential vanilloid type 1 (TRPV1) has also been reported to play a role in CNS disorders. Thus, activation of both targets, CB2 and TRPV1, offers a promising polypharmacological strategy for the treatment of neurological events including analgesia and neuroprotection. This brief research report aims to identify chemotypes with a potential dual CB2/TRPV1 profile. For this purpose, we have rationalized key structural features for activation and performed virtual screening at both targets using curated chemical libraries.

Abstract licence: CC BY

1. 45.

   Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease · 2016

2. 50.

   High-resolution crystal structure of the human CB1 cannabinoid receptor · 2016

3. 53.

   Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity · 2017

4. 55.

   Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target · 2017

5. 57.

   SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules · 2017

6. 63.

   Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors · 2017

7. 64.

   An Update on Non-CB 1 , Non-CB 2 Cannabinoid Related G-Protein-Coupled Receptors · 2017

8. 70.

   Cannabinoid Ligands Targeting TRP Channels · 2019

9. 77.

   Molecular mechanism of TRPV2 channel modulation by cannabidiol · 2019

10. 93.

    In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa · 2020

98 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.